Rapid Therapeutic Announces Its Plans to Utilize Its Proprietary Technology to Address Broad Applications for Delivery of Medications via the Pulmonary System to Focus on Addressable Markets of Over $7 Billion
DALLAS–(BUSINESS WIRE)–Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) (the “Company” or “RTSL”), a fully-reporting company with the U.S. Securities and Exchange Commission, is an innovative biotech company specializing in aerosol delivery of legal cannabinoids to the systemic blood stream though the pulmonary route of administration. RTSL manufactures white label products as well as its own…
Details